ADARx Pharmaceuticals Further Expands Leadership Team, Appointing Feriandas Greblikas, M.D. as VP of Clinical Development

ADARx Pharmaceuticals Further Expands Leadership Team, Appointing Feriandas Greblikas, M.D. as VP of Clinical Development




ADARx Pharmaceuticals Further Expands Leadership Team, Appointing Feriandas Greblikas, M.D. as VP of Clinical Development

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the further expansion of their leadership team and clinical development capabilities through the appointment of Feriandas Greblikas, M.D. as Vice President of Clinical Development.

“We are very excited to have Feriandas join the ADARx team,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “With his wealth of experience in drug development and clinical execution, he will make significant contributions to ADARx’s strategy, and operational effectiveness as we continue to advance programs to the clinic.”

Dr. Greblikas joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials later this year and two additional drug candidates are expected to enter clinical trials next year.

Dr. Greblikas is an established physician-scientist with more than 10 years of extensive experience in drug development, medical oversight, clinical trial planning and execution. Prior to joining ADARx, Dr. Greblikas served as a Senior Medical Director at Travere Therapeutics, in which he contributed to the development of pegtibatinase and fosmetpantothenate programs. Prior positions include Medical Director at BioMarin, Baxter and Biogen, and significant contributions to approved drugs Palynziq®, Adynovate® and Eloctate®. Dr. Greblikas received his M.D. in pediatrics from the Vilnius University. Dr. Greblikas also holds an Economics diploma from the International Business School of Vilnius University.

“I am delighted to join the passionate team at ADARx and be part of a shared commitment of bringing safe and effective treatments to patients with unmet needs,” said Dr. Greblikas. “The ADARx pipeline presents diverse options for first-in-class and best-in-class drugs to realize this commitment.”

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are entering clinical stage.

Contacts

ADARx Contact
Roselle Corbaley

(877) 232-7974

ir@adarx.com